Analogic Corporation Receives An Additional Order for Its EXplosive Assessment Computed Tomography Systems.

PEABODY, Mass. -- John W. Wood, President and CEO of Analogic Corporation (NASDAQ: ALOG), announced today that the Company has received an additional order for its EXplosive Assessment Computed Tomography (EXACT(TM)) Systems from L-3 Communications' (NYSE: LLL) subsidiary, L-3 Communications Security and Detection Systems, Inc. The order has a value of approximately $26,000,000 and will be fulfilled over the course of calendar 2005, with shipments beginning in the first quarter. Analogic is currently shipping units to fulfill an earlier order from L-3 that will be completed by the end of calendar 2004.

John Wood said, "We are pleased to receive this substantial order from L-3 Communications. These units will be the first built in our new 50,000 square foot security manufacturing facility at our headquarters in Peabody, which was completed earlier this year. We will be ramping up new production lines to meet the increased demand."

The EXACT is the "heart" of L-3's eXaminer(TM) 3DX 6000, a certified Explosive Detection System (EDS) that has been purchased by the U.S. Transportation Security Administration (TSA) and installed at major airports across the U.S. The L-3 systems are also installed at a number of leading international airports, including Israel's Ben Gurion Airport, Singapore's Changi Airport, and Italy's Fiumicino and Ciampino airports.

L-3 Communications recently announced that the company's eXaminer 3DX 6000 systems have been selected by the TSA for a break-bulk, air cargo screening pilot program at international airports in Miami, Chicago, Los Angeles, and Anchorage. The program's objective is to determine if it is possible and efficient to clear break-bulk cargo flown on commercial aircraft with the advanced automated explosives detection technology currently used to screen checked luggage for aircraft.

Analogic Corporation is a leading designer and manufacturer of advanced health and security systems and subsystems sold to Original Equipment Manufacturers (OEMs). The Company is recognized worldwide for advancing the state of the art in Computed Tomography (CT), Digital Radiography (DR), Ultrasound, Magnetic Resonance Imaging (MRI), Patient Monitoring, Cardiovascular Information Management, and Embedded Multiprocessing.

This press release reflects the Company's or management's intentions, hopes, beliefs, expectations, or predictions. These are considered "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements (statements that are not historical facts) in this press release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that all forward-looking statements, including statements about product development, market and industry trends, strategic initiatives, regulatory approvals, sales, profits, expenses, price trends, research and development trends, and capital expenditures, involve risks and uncertainties, and that actual events and results may differ significantly from those anticipated in such statements. Actual results may differ materially from those anticipated in such forward-looking statements as a result of various factors, including those discussed in the Company's periodic reports filed with the SEC.